Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Zavesca; Belgium: Zavesca; Bulgaria: Zavesca; Cyprus: Zavesca; Czech Republic: Zavesca; Denmark: Zavesca; Estonia: Zavesca; Finland: Zavesca; France: Zavesca; Germany: Zavesca; Greece: Zavesca; Hungary: Zavesca; Ireland: Zavesca; Italy: Zavesca; Latvia: Zavesca; Lithuania: Zavesca; Luxembourg: Zavesca; Malta: Zavesca; Netherlands: Zavesca; Poland: Zavesca; Portugal: Zavesca; Romania: Zavesca; Slovakia: Zavesca; Slovenia: Zavesca; Spain: Zavesca; Sweden: Zavesca; UK: Zavesca.

North America

Canada: Zavesca; USA: Zavesca.

Drug combinations


Miglustat: C~10~H~21~NO~4~. Mw: 219.28. (1) 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R,3R,4R,5S)-; (2)(2R,3R,4R,5S)-1-Butyl-2-(hydroxymethyl)piperidine-3,4,5-triol. CAS-72599-27-0 (2003).

Pharmacologic Category

Other Miscellaneous Therapeutic Agents; Enzyme Inhibitor. (ATC-Code: A16AX06).

Mechanism of action

Miglustat competitively and reversibly inhibits enzyme needed to produce glycosphingolipids and decreases rate of glycosphingolipid glucosylceramide formation.

Therapeutic use

Treatment of mild-to-moderate type 1 Gaucher’s disease when enzyme replacement therapy not a therapeutic option.

Pregnancy and lactiation implications

Decreased fetus weight, fetal loss, and difficult or delayed births observed in animal studies. Not recommended during lactation.

Unlabeled use


Hypersensitivity to miglustat or any component of the formulation. Pregnancy.

Warnings and precautions

Diarrhea common. Peripheral neuropathy reported. Exacerbations of existing tremor or tremor might occur. Use with caution in renal impairment. Not recommended in severe impairment. Miglustat increases clearance of imiglucerase.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart